The first and only FDA-approved treatment that chemoablates tumors in adult patients with low-grade UTUC
In contrast to adjuvant use of chemotherapy, JELMYTO is a primary treatment for low-grade UTUC
Instilled via a procedure that spares the kidney for tomorrow
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.
Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.
Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.